Mary S. Hinds

TL;DR: The clinical impression is that the current incidence of VOD at the institution is much higher than the 21% rate reported 9 years ago and that more patients have severe liver disease, which may explain the apparent increased incidence and severity of this complication.

TL;DR: Most cases of diarrhea after marrow transplant are not caused by infection, and clinical signs and symptoms of infection and GVHD were similar, and no clear etiology could be found for self-limited diarrhea.

TL;DR: The course of VOD after cytoreductive therapy can be predicted by knowing the serum bilirubin and weight gained within 1 to 2 weeks of transplantation, and probability estimates derived from patient data are highly specific and moderately sensitive.

TL;DR: It is concluded that recombinant human tPA can be administered to patients with severe VOD at the dosage described and five patients responded to therapy with prompt reduction in total serum bilirubin within 96 hours of starting tPA.

TL;DR: It is concluded that P GE1 causes significant toxicity in patients undergoing marrow transplantation and the ability of PGE1 to prevent severe VOD in patients at high risk remains unproven.